Everolimus drug‐eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry
| العنوان: | Everolimus drug‐eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry |
|---|---|
| المؤلفون: | Bruno García del Blanco, Christophe Bretelle, Santiago Jesús Camacho Freire, Nicolas Delarche, Ramón López Palop, Franck Albert, Javier Zueco Gil, Vicente Mainar Tello, José Francisco Díaz Fernández, Juan Carlos Fernández Guerrero |
| المصدر: | Catheterization and Cardiovascular Interventions. 92:E493-E501 |
| بيانات النشر: | Wiley, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Population, Coronary Artery Disease, 030204 cardiovascular system & hematology, Prosthesis Design, Lesion, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Intravascular ultrasound, medicine, Humans, Radiology, Nuclear Medicine and imaging, Everolimus, Prospective Studies, Registries, cardiovascular diseases, 030212 general & internal medicine, Myocardial infarction, Angioplasty, Balloon, Coronary, education, Aged, education.field_of_study, medicine.diagnostic_test, business.industry, Stent, Percutaneous coronary intervention, Cardiovascular Agents, Drug-Eluting Stents, General Medicine, Middle Aged, medicine.disease, Surgery, Europe, Treatment Outcome, Drug-eluting stent, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Mace |
| الوصف: | Objectives To assess the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions in a real-world population. Background Long lesions are considered difficult technically and in terms of achieving successful clinical outcomes. With first generation DES, MACE can be as high as 10% at a short-medium term follow-up. There are a few data available in this subset regarding the use of second generation DES METHODS: A prospective, multicenter registry of consecutive patients (aged 64.8 ± 11.2 years, 77% men and 33% diabetics) in 29 tertiary hospitals with de novo > 24 mm lesions in vessels of 2.25-4 mm was performed. The primary and secondary endpoints were major adverse cardiac events (MACE; cardiac death, myocardial infarction, and target lesion revascularization) and stent thrombosis (ST) at 1, 12, and 24 months. Patients were on dual antiplatelet therapy during 12 months. Results A total of 610 patients with 705 long lesions were included (1.2 per patient). Lesion length was 34.59 ± 11.17 mm and vessel size 2.93 ± 0.41 mm. Stented length was 39.83 ± 14.08 mm (1.4 stents per lesion). Predilatation/postdiltatation was performed in 75 and 33% of the cases, intravascular ultrasound in 15%. The device success rate was 99.1%. MACE and ST rates at 1, 12, and 24-months follow-up were 0.3, 2.1, and 5.4% and 0.2, 0.7, and 1.5%, respectively. Conclusion In this real-world population, the Xience Prime EES performs extremely well in long lesions, with a very low rate of both MACE and ST. |
| تدمد: | 1522-726X 1522-1946 |
| DOI: | 10.1002/ccd.27657 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974d0d3b0cb35268ee71cce704f9d588 https://doi.org/10.1002/ccd.27657 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....974d0d3b0cb35268ee71cce704f9d588 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1522726X 15221946 |
|---|---|
| DOI: | 10.1002/ccd.27657 |